AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

Core Insights - AEON Biopharma is advancing ABP-450 as a biosimilar to BOTOX, aiming for accelerated and full-label U.S. market entry [1] - The company will present data at the 2026 American Academy of Neurology Annual Meeting, highlighting the analytical similarity of ABP-450 to the reference product [2][3] Company Overview - AEON Biopharma focuses on the U.S. therapeutic neurotoxin market, which exceeds $3.0 billion annually, presenting significant opportunities for biosimilar competition [5] - ABP-450 is manufactured by Daewoong Pharmaceutical under cGMP and is already approved as a biosimilar in India, Mexico, and the Philippines [5] - The company holds exclusive development and distribution rights for ABP-450 in the U.S., Canada, the EU, the UK, and other territories [5] Presentation Details - The poster presentation titled "Establishing Primary Structure Comparability Between ABP-450 and OnabotulinumtoxinA (Botox) to Support Biosimilarity" will take place on April 22, 2026 [4] - The session will be presented by Chad K. Oh, M.D., Chief Medical Officer of AEON Biopharma [4]